Cargando…
Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study
BACKGROUND: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple stud...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242279/ https://www.ncbi.nlm.nih.gov/pubmed/34193235 http://dx.doi.org/10.1186/s13054-021-03648-9 |
_version_ | 1783715600185425920 |
---|---|
author | Al Sulaiman, Khalid Aljuhani, Ohoud Al Dossari, Maram Alshahrani, Asma Alharbi, Aisha Algarni, Rahmah Al Jeraisy, Majed Al Harbi, Shmeylan Al Katheri, Abdulmalik Al Eidan, Fahad Al Bekairy, Abdulkareem M. Al Qahtani, Nouf Al Muqrin, Mashael Vishwakarma, Ramesh Al Ghamdi, Ghassan |
author_facet | Al Sulaiman, Khalid Aljuhani, Ohoud Al Dossari, Maram Alshahrani, Asma Alharbi, Aisha Algarni, Rahmah Al Jeraisy, Majed Al Harbi, Shmeylan Al Katheri, Abdulmalik Al Eidan, Fahad Al Bekairy, Abdulkareem M. Al Qahtani, Nouf Al Muqrin, Mashael Vishwakarma, Ramesh Al Ghamdi, Ghassan |
author_sort | Al Sulaiman, Khalid |
collection | PubMed |
description | BACKGROUND: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it’s role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients. METHODS: This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching. RESULTS: A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19–0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18–0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04–0.88), P value = 0.03]. CONCLUSION: Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03648-9. |
format | Online Article Text |
id | pubmed-8242279 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-82422792021-06-30 Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study Al Sulaiman, Khalid Aljuhani, Ohoud Al Dossari, Maram Alshahrani, Asma Alharbi, Aisha Algarni, Rahmah Al Jeraisy, Majed Al Harbi, Shmeylan Al Katheri, Abdulmalik Al Eidan, Fahad Al Bekairy, Abdulkareem M. Al Qahtani, Nouf Al Muqrin, Mashael Vishwakarma, Ramesh Al Ghamdi, Ghassan Crit Care Research BACKGROUND: Thiamine is a precursor of the essential coenzyme thiamine pyrophosphate required for glucose metabolism; it improves the immune system function and has shown to reduce the risk of several diseases. The role of thiamine in critically ill septic patient has been addressed in multiple studies; however, it’s role in COVID-19 patients is still unclear. The aim of this study was to evaluate the use of thiamine as an adjunctive therapy on mortality in COVID-19 critically ill patients. METHODS: This is a two-center, non-interventional, retrospective cohort study for critically ill patients admitted to intensive care units (ICUs) with a confirmed diagnosis of COVID19. All patients aged 18 years or older admitted to ICUs between March 1, 2020, and December 31, 2020, with positive PCR COVID-19 were eligible for inclusion. We investigated thiamine use as an adjunctive therapy on the clinical outcomes in critically ill COVID-19 patients after propensity score matching. RESULTS: A total of 738 critically ill patients with COVID-19 who had been admitted to ICUs were included in the study. Among 166 patients matched using the propensity score method, 83 had received thiamine as adjunctive therapy. There was significant association between thiamine use with in-hospital mortality (OR = 0.39; 95% CI 0.19–0.78; P value = 0.008) as well as the 30-day mortality (OR = 0.37; 95% CI 0.18–0.78; P value = 0.009). Moreover, patients who received thiamine as an adjunctive therapy were less likely to have thrombosis during ICU stay [OR (95% CI) 0.19 (0.04–0.88), P value = 0.03]. CONCLUSION: Thiamine use as adjunctive therapy may have potential survival benefits in critically ill patients with COVID-19. Additionally, it was associated with a lower incidence of thrombosis. Further interventional studies are required to confirm these findings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13054-021-03648-9. BioMed Central 2021-06-30 /pmc/articles/PMC8242279/ /pubmed/34193235 http://dx.doi.org/10.1186/s13054-021-03648-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Al Sulaiman, Khalid Aljuhani, Ohoud Al Dossari, Maram Alshahrani, Asma Alharbi, Aisha Algarni, Rahmah Al Jeraisy, Majed Al Harbi, Shmeylan Al Katheri, Abdulmalik Al Eidan, Fahad Al Bekairy, Abdulkareem M. Al Qahtani, Nouf Al Muqrin, Mashael Vishwakarma, Ramesh Al Ghamdi, Ghassan Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title | Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title_full | Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title_fullStr | Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title_full_unstemmed | Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title_short | Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study |
title_sort | evaluation of thiamine as adjunctive therapy in covid-19 critically ill patients: a two-center propensity score matched study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8242279/ https://www.ncbi.nlm.nih.gov/pubmed/34193235 http://dx.doi.org/10.1186/s13054-021-03648-9 |
work_keys_str_mv | AT alsulaimankhalid evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT aljuhaniohoud evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT aldossarimaram evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alshahraniasma evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alharbiaisha evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT algarnirahmah evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT aljeraisymajed evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alharbishmeylan evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alkatheriabdulmalik evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT aleidanfahad evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT albekairyabdulkareemm evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alqahtaninouf evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT almuqrinmashael evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT vishwakarmaramesh evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy AT alghamdighassan evaluationofthiamineasadjunctivetherapyincovid19criticallyillpatientsatwocenterpropensityscorematchedstudy |